TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05427591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The chemomechanical caries removal agent BRIX3000® in group (1A)
Description: In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The traditional surgical treatment in group (1C)
Description: In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The chemomechanical caries removal agent Carie-CareTM in group (2B)
Description: In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars.
Study: NCT01363479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT05566405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anaesthesia
Description: All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
Study: NCT05427591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The traditional surgical treatment in group (2C)
Description: In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
Study: NCT04796571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Symptom Monitoring and Care Coordination
Description: Patients randomized to the intervention arm were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care. Symptom monitoring was facilitated through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. The IBD-focused care coordinator made two attempts to reach each participant using portal messaging, followed by a phone call to reduce non-response. PRO questionnaires were reviewed by the care coordinator and out of range scores triggered algorithm-based recommendations to the IBD specialist including stricter monitoring of disease activity, behavioral and medication adherence counseling, facilitation of expedited follow-up with treating providers, and referrals to social work, mental health, and gastroenterology-specific behavioral health services.
Study: NCT05566405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined (Epidural and Spinal) Anaesthesia
Description: Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Retropubic Radical Prostatectomy
Description: All patients will undergo a nerve-sparing open retropubic radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Retropubic Radical Prostatectomy
Description: All patients will undergo a nerve-sparing open retropubic radical prostatectomy
Study: NCT01049620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Capecitabine, Oxaliplatin
Description: Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21
Study: NCT02354183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Skills Training
Description: Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
Study: NCT02155686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosensors
Description: Device: Biometric sensors; Home automation; telecare

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home automation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home automation
Study: NCT02354183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DBT Skills Training
Description: Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
Study: NCT03926247

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Immigrant Well-Being Project
Description: The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
Study: NCT03048825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone 25 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone 25 mg once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY Bioabsorbable Polymer Drug-Eluting Stent
Description: Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY Bioabsorbable Polymer Drug-Eluting Stent
Description: Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SYNERGY Bioabsorbable Polymer Drug-Eluting Stent
Description: Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY Bioabsorbable Polymer Drug-Eluting Stent
Description: Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine-Placebo
Description: Matching Colchicine-placebo once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine-Placebo
Description: Matching Colchicine-placebo once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone-Placebo
Description: Matching Spironolactone-Placebo once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone-Placebo
Description: Matching Spironolactone-Placebo once daily
Study: NCT00608790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride 5%
Description: 30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
Study: NCT04796805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical essential oil application
Description: We applied black pepper essential oil to the participants in experimental group before the catheter insertion procedure
Study: NCT02955082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous carboplatin infusion every 3 weeks.
Study: NCT01954511

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Manual therapy
Description: The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Manual therapy
Description: The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Pressure biofeedback device
Description: Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
Study: NCT01678365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole
Study: NCT01046994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biliopancreatic diversion
Description: biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidiabetics
Description: patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
Study: NCT01432431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spiritual therapy
Description: Undergo palliative spiritual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo palliative spiritual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial support for caregiver
Description: Undergo palliative spiritual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Undergo palliative spiritual care
Study: NCT03340935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet
Description: Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
Study: NCT02481141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-ALA-SFC
Description: Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00833274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computerized test
Description: Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
Study: NCT03742726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Matrix scaffold
Description: Smart Matrix dermal replacement scaffold
Study: NCT02184286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir-sgc
Description: 1600 mg b.i.d. from pre trial to day 28
Study: NCT02096003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: 0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal hydromorphone
Description: 50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
Study: NCT03182803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTLA-4/PD-1 antibodies expressing mesoCAR-T
Description: Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
Study: NCT00603785

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
Study: NCT00005602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cereport

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cereport

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cereport

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cereport

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03828409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short stitch
Description: The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short stitch
Description: The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.
Study: NCT02214706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser
Study: NCT02781558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04933357

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose escalation
Description: Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose
Description: Standard dose to good responders to achieve dose equivalent of 70 Gy.
Study: NCT04422652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion is an anti-depressant medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral activation therapy
Description: Brief behavioral activation treatments administered via video tele-conferencing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Management
Description: Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Management
Description: Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
Study: NCT00799708

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo capsule once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Estrace
Description: Estrace 0.5 mg or 2 mg tablets once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Estrace
Description: Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
Study: NCT01087034

Intervention type: DEVICE
Intervention: Acoustic reflection method evaluation
Description: Evaluation of airways by acoustic relection method, with and without the bracing device

Intervention type: DEVICE
Intervention: Acoustic reflection method evaluation
Description: Evaluation of airways by acoustic relection method, with and without the bracing device

Intervention type: RADIATION
Intervention: EOS™
Description: Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device

Intervention type: RADIATION
Intervention: EOS™
Description: Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device

Intervention type: OTHER
Intervention: Non invasive respiratory muscle assessment
Description: Non invasive respiratory muscles assessment, with and without the bracing device.

Intervention type: OTHER
Intervention: Non invasive respiratory muscle assessment
Description: Non invasive respiratory muscles assessment, with and without the bracing device.
Study: NCT03768817

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
Study: NCT01115933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE PRIME SV EECSS
Description: Patients receiving XIENCE PRIME SV EECSS
Study: NCT04217538

Intervention type: OTHER
Intervention: clinical exam
Description: clinical oral examination
Study: NCT01656798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: 2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: 2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
Study: NCT00481026

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Active tDCS
Study: NCT02351167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination NRT (Nicotine patch, Nicotine lozenge)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive smoking counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive smoking counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive smoking counseling